Europe has become the first region to authorize Moderna's mRNA combination vaccine for both flu and COVID-19, marking a significant milestone in respiratory virus prevention. The vaccine, called mCOMBRIAX, demonstrated superior immune responses compared to standard vaccines in Phase III trials involving 4,000 adults. While available across the EU, the vaccine remains unapproved in the US where it was developed, highlighting regulatory differences.
Background
mRNA vaccine technology gained prominence during the COVID-19 pandemic, with Moderna being one of the leading developers. Combination vaccines represent the next frontier in streamlining immunization against multiple respiratory viruses.
- Source
- Ars Technica
- Published
- Apr 25, 2026 at 05:11 AM
- Score
- 7.0 / 10